Adjuvant Chemotherapy Combined With Trastuzumab in the Randomized Phase III Trial N9831 Actively Immunizes Patients Against Tumor Antigens [SUBSTUDY OF 700003274]
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2019
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2016 Planned primary completion date changed from 1 Feb 2013 to 1 Jan 2100.